股本结构
单位：万股
| 公告日期 | 2024-12-04 | 2024-11-14 | 2024-11-14 | 2024-08-09 | 2024-08-09 | 2024-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 205.39 | 191.16 | 160.42 | 143.14 | 118.97 | 94.10 |
| 普通股本 | 205.39 | 191.16 | 160.42 | 143.14 | 118.97 | 94.10 |
| 优先股 | 未披露 | 未披露 | 25.00 | 未披露 | 25.00 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-12-03 | 2024-11-11 | 2024-09-30 | 2024-08-07 | 2024-06-30 | 2024-05-13 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-12-04 | 205.39 | 未披露 | 定期报告 | 2024-12-03 |
| 2024-11-14 | 191.16 | 未披露 | 定期报告 | 2024-11-11 |
| 2024-11-14 | 160.42 | 25.00 |
更多>>
From June 30, 2024 to September 30, 2024
Common shares issuable - Founders Agreement
Exercise of warrants
Issuance of common stock, net of offering costs under open market sales agreement (ATM)
|
2024-09-30 |
| 2024-08-09 | 143.14 | 未披露 | 定期报告 | 2024-08-07 |
| 2024-08-09 | 118.97 | 25.00 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock to Fortress
Exercise of warrants
Reverse split (1-for-75)
Issuance of common stock, net of offering costs under open market sales agreement (ATM)
|
2024-06-30 |
| 2024-05-15 | 94.10 | 未披露 | 定期报告 | 2024-05-13 |
| 2024-05-10 | 94.08 | 未披露 | 定期报告 | 2024-05-08 |
| 2024-05-06 | 76.98 | 未披露 | 定期报告 | 2024-05-02 |
| 2024-05-06 | 59.55 | 25.00 | 定期报告 | 2024-04-30 |
| 2024-04-24 | 60.00 | 未披露 |
更多>>
1-for-75 reverse split of its issued and outstanding common stock
|
2024-04-26 |
| 2024-04-24 | 4470.00 | 未披露 | 定期报告 | 2024-04-24 |
| 2024-03-18 | 4426.07 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-01-29 | 3730.54 | 25.00 | 定期报告 | 2024-01-09 |
| 2024-01-24 | 3730.54 | 未披露 | 定期报告 | 2024-01-05 |
| 2024-01-24 | 2772.04 | 未披露 | 定期报告 | 2024-01-04 |
| 2024-03-18 | 2559.76 | 25.00 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common stock to Fortress
Issuance of common stock and pre-funded warrants, net of offering costs - November 2023 public offering
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement
Issuance of common stock for license expense
Exercise of warrants
Shares issued in a private placement offering
|
2023-12-31 |
| 2023-11-13 | 1324.76 | 未披露 | 定期报告 | 2023-11-08 |
| 2023-11-02 | 2559.76 | 未披露 |
更多>>
Units Offered 16,633,400 units by the company,each unit consisting of (A) one share of Common Stock, (B) one Series A warrant exercisable for one share of Common Stock and (C) one Series B warrant exercisable for one share of Common Stock.
|
2023-11-02 |
| 2023-11-13 | 896.42 | 25.00 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock for license expense
Shares issued in a private placement offering
|
2023-09-30 |
| 2023-09-29 | 896.42 | 未披露 | 定期报告 | 2023-09-26 |
| 2023-08-11 | 818.30 | 未披露 | 定期报告 | 2023-08-07 |
| 2023-08-11 | 792.05 | 25.00 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of warrants
|
2023-06-30 |
| 2023-06-16 | 790.73 | 25.00 | 定期报告 | 2023-05-08 |
| 2023-04-28 | 792.05 | 25.00 | 定期报告 | 2023-04-25 |
| 2023-05-12 | 682.82 | 25.00 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock to Fortress
Issuance of common stock for license acquisition
Exercise of warrants
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement
|
2023-03-31 |
| 2023-03-31 | 594.41 | 未披露 | 定期报告 | 2023-03-28 |
| 2023-01-31 | 553.09 | 未披露 |
更多>>
Common Stock offered 448,000 shares by the company
|
2023-01-31 |
| 2023-01-31 | 508.29 | 未披露 | 定期报告 | 2023-01-26 |
| 2023-03-31 | 477.38 | 25.00 |
更多>>
From December 31, 2021 to December 31, 2022
Share based compensation
Issuance of common shares and pre-funded warrants at private placement, net of issuance costs
Repurchase of common stock held by InvaGen
Exercise of warrants
|
2022-12-31 |
| 2022-11-18 | 477.93 | 25.00 | 定期报告 | 2022-11-10 |
| 2022-11-10 | 477.33 | 未披露 | 定期报告 | 2022-11-01 |
| 2022-10-11 | 415.21 | 未披露 |
更多>>
the company is offering 2,652,065 Common Stocks
|
2022-10-11 |
| 2022-11-10 | 148.14 | 25.00 |
更多>>
From June 30, 2022 to September 30, 2022
Share based compensation
|
2022-09-30 |
| 2022-09-22 | 150.00 | 未披露 |
更多>>
Avenue Therapeutics, Inc. announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 23, 2022.
|
2022-09-23 |
| 2022-09-22 | 2270.00 | 未披露 | 定期报告 | 2022-09-22 |
| 2022-08-22 | 2198.77 | 25.00 | 定期报告 | 2022-07-25 |
| 2022-05-16 | 2213.48 | 25.00 |
更多>>
From December 31, 2021 to March 31, 2022
Share based compensation
|
2022-03-31 |
| 2022-03-25 | 2173.23 | 未披露 | 定期报告 | 2022-03-21 |
| 2022-03-25 | 2108.97 | 25.00 |
更多>>
From December 31, 2020 to December 31, 2021
Share based compensation
Issuance of common shares, net of costs
Cashless exercise of warrants
|
2021-12-31 |
| 2021-12-15 | 1870.38 | 未披露 |
更多>>
1.Common stock offered by company 1,910,100 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 16,793,693 shares of common stock outstanding as of September 30, 2021.
|
2021-12-15 |
| 2021-11-23 | 1899.25 | 25.00 | 定期报告 | 2021-11-22 |
| 2021-11-15 | 1870.05 | 未披露 |
更多>>
1.Common stock offered 1,946,787 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 16,748,068 shares of common stock outstanding as of June 30, 2021.
|
2021-11-12 |
| 2021-11-15 | 1679.37 | 25.00 |
更多>>
From June 30, 2021 to September 30, 2021
Share based compensation
Cashless exercise of warrants
|
2021-09-30 |
| 2021-09-28 | 1679.31 | 未披露 | 定期报告 | 2021-09-21 |
| 2021-05-17 | 1674.81 | 25.00 |
更多>>
From December 31, 2020 to March 31, 2021
Cashless exercise of warrants
|
2021-03-31 |
| 2021-03-31 | 1674.81 | 未披露 | 定期报告 | 2021-03-17 |
| 2020-11-04 | 1674.78 | 25.00 |
更多>>
From June 30, 2020 to September 30, 2020
Share based compensation
|
2020-09-30 |
| 2020-08-14 | 1670.28 | 25.00 |
更多>>
From March 31, 2020 to June 30, 2020
Share based compensation
|
2020-06-30 |
| 2020-05-11 | 1668.28 | 25.00 |
更多>>
From December 31, 2019 to March 31, 2020
Cashless exercise of warrants under the NSC Note
|
2020-03-31 |
| 2020-03-30 | 1668.28 | 未披露 | 定期报告 | 2020-03-29 |
| 2020-03-30 | 1668.22 | 25.00 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common shares, net of costs
Cashless exercise of warrants under the NSC Note
Share based compensation
|
2019-12-31 |
| 2019-11-13 | 1666.14 | 25.00 |
更多>>
From June 30, 2019 to September 30, 2019
Share based compensation
Cashless exercise of warrants under the NSC Note
|
2019-09-30 |
| 2019-08-14 | 1656.01 | 未披露 | 定期报告 | 2019-08-01 |
| 2019-08-14 | 1655.97 | 25.00 |
更多>>
From March 31, 2019 to June 30, 2019
Cashless exercise of warrants under the NSC Note
|
2019-06-30 |
| 2019-05-13 | 1655.92 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-04-30 | 1655.87 | 未披露 | 定期报告 | 2019-04-26 |
| 2019-05-13 | 1655.71 | 25.00 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of common shares, net of costs
Cashless exercise of warrants under the NSC Note
|
2019-03-31 |
| 2019-03-12 | 1650.23 | 未披露 | 定期报告 | 2019-02-08 |
| 2019-03-12 | 1066.77 | 25.00 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
Share based compensation
|
2018-12-31 |
| 2018-12-21 | 1066.77 | 未披露 | 定期报告 | 2018-12-13 |
| 2018-11-14 | 1066.24 | 25.00 |
更多>>
from December 31, 2017 to September 30, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
Share based compensation
|
2018-09-30 |
| 2018-08-14 | 1055.44 | 未披露 | 定期报告 | 2018-08-06 |
| 2018-08-14 | 1055.42 | 25.00 |
更多>>
from December 31, 2017 to June 30, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
|
2018-06-30 |
| 2018-04-30 | 1055.30 | 25.00 | 定期报告 | 2018-04-16 |
| 2018-04-13 | 1055.30 | 未披露 | 定期报告 | 2018-04-11 |
| 2018-05-03 | 1055.20 | 25.00 |
更多>>
from December 31, 2017 to March 31, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
|
2018-03-31 |
| 2018-03-01 | 1027.71 | 未披露 | 定期报告 | 2018-02-14 |
| 2018-03-01 | 1026.51 | 25.00 |
更多>>
from December 31, 2016 to December 31, 2017
Share based compensation
Issuance of common shares - Founders Agreement
Issuance of common shares, net of costs
Conversion of MSA fees into common shares
Exercise of warrants under the NSC Note
Conversion of notes payable
Common shares issuable to Fortress - Founders
|
2017-12-31 |
| 2017-11-09 | 1026.52 | 25.00 |
更多>>
From December 31, 2016 to September 30, 2017
Share based compensation
Issuance of common shares - Founders Agreement
Issuance of common shares, net of costs
Conversion of MSA fees into common shares
Conversion of notes payable
|
2017-09-30 |
| 2017-08-11 | 1004.10 | 8.33 |
更多>>
From December 31, 2016 to June 30, 2017
Issuance of common shares - Founders Agreement
Issuance of common shares, net of costs
Conversion of MSA fees into common shares
Conversion of notes payable
|
2017-06-30 |
| 2017-06-28 | 884.15 | 未披露 |
更多>>
1.Common stock offered by us 5,500,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 3,341,468 shares of our common stock outstanding as of March 31, 2017, after giving effect to our 3 for 1 reverse stock split, representing 3,257,937 shares of our common stock outstanding and 83,531 shares of our common stock issued to Fortress pursuant to the PIK Dividend
|
2017-06-27 |
| 2017-05-12 | 334.15 | 25.00 |
更多>>
From December 31, 2016 to March 31, 2017
Issuance of common shares - Founders Agreement
3,341,468 shares of our common stock outstanding as of March 31, 2017, after giving effect to our proposed 3 for 1 reverse stock split
|
2017-03-31 |
| 2017-04-28 | 977.38 | 25.00 |
更多>>
From December 31, 2015 to December 31, 2016
Conversion Class A common shares to Class A preferred shares and common shares
Issuance of common shares – Founders Agreement
Retirement of common shares
Common shares issuable to Fortress per Founders Agreement
|
2016-12-31 |
From June 30, 2024 to September 30, 2024
Common shares issuable - Founders Agreement
Exercise of warrants
Issuance of common stock, net of offering costs under open market sales agreement (ATM)
From March 31, 2024 to June 30, 2024
Issuance of common stock to Fortress
Exercise of warrants
Reverse split (1-for-75)
Issuance of common stock, net of offering costs under open market sales agreement (ATM)
1-for-75 reverse split of its issued and outstanding common stock
From December 31,2022 to December 31,2023
Issuance of common stock to Fortress
Issuance of common stock and pre-funded warrants, net of offering costs - November 2023 public offering
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement
Issuance of common stock for license expense
Exercise of warrants
Shares issued in a private placement offering
Units Offered 16,633,400 units by the company,each unit consisting of (A) one share of Common Stock, (B) one Series A warrant exercisable for one share of Common Stock and (C) one Series B warrant exercisable for one share of Common Stock.
From June 30, 2023 to September 30, 2023
Issuance of common stock for license expense
Shares issued in a private placement offering
From March 31, 2023 to June 30, 2023
Exercise of warrants
From December 31, 2022 to March 31, 2023
Issuance of common stock to Fortress
Issuance of common stock for license acquisition
Exercise of warrants
Issuance of common stock and pre-funded warrants, net of offering costs - registered direct offering and private placement
Common Stock offered 448,000 shares by the company
From December 31, 2021 to December 31, 2022
Share based compensation
Issuance of common shares and pre-funded warrants at private placement, net of issuance costs
Repurchase of common stock held by InvaGen
Exercise of warrants
the company is offering 2,652,065 Common Stocks
From June 30, 2022 to September 30, 2022
Share based compensation
Avenue Therapeutics, Inc. announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 23, 2022.
From December 31, 2021 to March 31, 2022
Share based compensation
From December 31, 2020 to December 31, 2021
Share based compensation
Issuance of common shares, net of costs
Cashless exercise of warrants
1.Common stock offered by company 1,910,100 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 16,793,693 shares of common stock outstanding as of September 30, 2021.
1.Common stock offered 1,946,787 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 16,748,068 shares of common stock outstanding as of June 30, 2021.
From June 30, 2021 to September 30, 2021
Share based compensation
Cashless exercise of warrants
From December 31, 2020 to March 31, 2021
Cashless exercise of warrants
From June 30, 2020 to September 30, 2020
Share based compensation
From March 31, 2020 to June 30, 2020
Share based compensation
From December 31, 2019 to March 31, 2020
Cashless exercise of warrants under the NSC Note
From December 31, 2018 to December 31, 2019
Issuance of common shares, net of costs
Cashless exercise of warrants under the NSC Note
Share based compensation
From June 30, 2019 to September 30, 2019
Share based compensation
Cashless exercise of warrants under the NSC Note
From March 31, 2019 to June 30, 2019
Cashless exercise of warrants under the NSC Note
From December 31, 2018 to March 31, 2019
Issuance of common shares, net of costs
Cashless exercise of warrants under the NSC Note
from December 31, 2017 to December 31, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
Share based compensation
from December 31, 2017 to September 30, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
Share based compensation
from December 31, 2017 to June 30, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
from December 31, 2017 to March 31, 2018
Issuance of common shares - Founders Agreement
Exercise of warrants under the NSC Note
from December 31, 2016 to December 31, 2017
Share based compensation
Issuance of common shares - Founders Agreement
Issuance of common shares, net of costs
Conversion of MSA fees into common shares
Exercise of warrants under the NSC Note
Conversion of notes payable
Common shares issuable to Fortress - Founders
From December 31, 2016 to September 30, 2017
Share based compensation
Issuance of common shares - Founders Agreement
Issuance of common shares, net of costs
Conversion of MSA fees into common shares
Conversion of notes payable
From December 31, 2016 to June 30, 2017
Issuance of common shares - Founders Agreement
Issuance of common shares, net of costs
Conversion of MSA fees into common shares
Conversion of notes payable
1.Common stock offered by us 5,500,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 3,341,468 shares of our common stock outstanding as of March 31, 2017, after giving effect to our 3 for 1 reverse stock split, representing 3,257,937 shares of our common stock outstanding and 83,531 shares of our common stock issued to Fortress pursuant to the PIK Dividend
From December 31, 2016 to March 31, 2017
Issuance of common shares - Founders Agreement
3,341,468 shares of our common stock outstanding as of March 31, 2017, after giving effect to our proposed 3 for 1 reverse stock split
From December 31, 2015 to December 31, 2016
Conversion Class A common shares to Class A preferred shares and common shares
Issuance of common shares – Founders Agreement
Retirement of common shares
Common shares issuable to Fortress per Founders Agreement